| Literature DB >> 34408500 |
Tiruye Menshw1, Shiferaw Birhanu2, Tigist Gebremaryam3, Worke Yismaw1, Aklilu Endalamaw2,4.
Abstract
BACKGROUND: It is known that antiretroviral therapy reduces the transmission of human immunodeficiency virus and AIDS-related morbidity. The coverage of HIV drugs is increasing to control further spread of HIV and children living with HIV are the target groups in using these medications. However, loss to follow-up remains a critical challenge among these groups of the population. The aim of this study was therefore to assess the incidence and predictors of loss to follow-up among children attending antiretroviral therapy clinics.Entities:
Keywords: Ethiopia; incidence; loss to follow up; predictors
Year: 2021 PMID: 34408500 PMCID: PMC8364847 DOI: 10.2147/HIV.S320601
Source DB: PubMed Journal: HIV AIDS (Auckl) ISSN: 1179-1373
Baseline Sociodemographic Characteristics of Children on ART in Northeast Ethiopia, 2020
| Variable | Frequency | Percent | |
|---|---|---|---|
| Sex of children | Male | 258 | 52.9 |
| Female | 230 | 47.1 | |
| Age of children | ≥ 5 years | 341 | 69.5 |
| 1–5 years | 125 | 25.6 | |
| < 1 years | 22 | 4.5 | |
| Relation of child to care giver | Parent | 416 | 85.2 |
| Guardian | 72 | 14.8 | |
| Religion of parent/care giver | Muslim | 299 | 61.3 |
| Orthodox | 171 | 35.0 | |
| Other* | 18 | 3.7 | |
| Residence | Urban | 371 | 76 |
| Rural | 117 | 24 | |
| Age of parent/care giver | ≥ 35 years | 258 | 52.9 |
| < 35 years | 230 | 47.1 | |
| Sex of parent/care giver | Male | 125 | 25.6 |
| Female | 363 | 74.4 | |
| Marital status of caregiver | Married | 341 | 69.9 |
| Single | 18 | 3.7 | |
| Widowed | 74 | 15.1 | |
| Divorced | 55 | 11.3 | |
| HIV status of parent/caregiver | Both parents positive | 148 | 30.3 |
| Mother positive | 241 | 49.4 | |
| Father positive | 29 | 5.9 | |
| Father negative | 7 | 1.4 | |
| Care giver positive | 1 | 0.2 | |
| Care giver negative | 24 | 4.9 | |
| Unknown | 38 | 7.8 | |
| Parent status | Both alive | 348 | 71.3 |
| Only mother alive | 57 | 11.7 | |
| Only father alive | 29 | 5.9 | |
| Both died | 33 | 6.8 | |
| Unknown | 21 | 4.3 | |
| Occupation of parent /care giver | Farmer | 94 | 19.3 |
| Merchant | 92 | 18.9 | |
| Government employee | 94 | 19.3 | |
| Daily worker | 59 | 12.1 | |
| House wife | 145 | 29.7 | |
| Other ** | 4 | 0.8 | |
| Place of delivery of child | Health facility | 237 | 48.6 |
| Home | 251 | 74.4 |
Notes: *Catholic and protestant. **Students and waiters.
Baseline Clinical, Laboratory, and ART Information of Children on ART in Northeast Ethiopia, 2020
| Variable | Frequency | Percent | |
|---|---|---|---|
| Presence of OIs at base line | Yes | 356 | 73.2 |
| No | 132 | 26.8 | |
| Type of OIs | Pneumonia | 66 | 18.9 |
| Pulmonary tuberculosis | 29 | 8.1 | |
| Upper respiratory tract infection | 45 | 12.6 | |
| Unexplained wasting and stunting | 4 | 1.1 | |
| Diarrhea | 56 | 15.7 | |
| Unexplained Fever | 26 | 7.3 | |
| Herpes zoster | 44 | 12.3 | |
| Oral candidiasis | 25 | 7 | |
| Skin dermatitis | 49 | 13.7 | |
| Other* | 13 | 3.64 | |
| Functional status ≥ 5 years (n=341) | Working | 324 | 95 |
| Ambulatory | 10 | 2.9 | |
| Bed-ridden | 7 | 2.1 | |
| Developmental status < 5 years (n=147) | Appropriate | 121 | 82.3 |
| Delayed | 24 | 16.3 | |
| Regressed | 2 | 1.4 | |
| WHO staging | Stage I | 134 | 27.5 |
| Stage II | 171 | 35 | |
| Stage III | 166 | 34 | |
| Stage IV | 17 | 3.5 | |
| Hemoglobin level | ≥ 10 mg/dl | 431 | 88.3 |
| < 10 mg/dl | 57 | 11.7 | |
| CD4 count | ≥350 cells | 227 | 46.5 |
| < 350 cells | 261 | 53.5 | |
| Eligibility criteria | Clinical (WHO staging) | 50 | 10.2 |
| CD4 count | 235 | 48.2 | |
| Without criteria | 139 | 28.5 | |
| DBS positive | 28 | 5.7 | |
| Both clinical and CD4 count | 36 | 7.4 | |
| Baseline regimen | 4a(d4t-3TC-NVP) | 116 | 23.8 |
| 4b(d4t-3TC-EFV | 51 | 10.5 | |
| 4c(AZT-3TC-NV) | 137 | 28.1 | |
| 4d(AZT-3TC-EFV | 88 | 18 | |
| 1e(TDF-3TC-EFV) | 51 | 10.5 | |
| 1h(ABC-3TC-NVP) | 9 | 1.8 | |
| 1g(ABC-3TC-EFV) | 15 | 3.1 | |
| 4g(ABC-3TC-LPV/r) | 17 | 3.5 | |
| Other (1c,4i,4j) | 4 | 0.8 | |
| Taking prophylaxis | Yes | 452 | 92.6 |
| No | 36 | 7.4 | |
| Type of prophylaxis | CPT | 440 | 96.3 |
| INH | 13 | 2.8 | |
| Both CPTand INH | 4 | 0.9 | |
| Side effects | Yes | 34 | 7 |
| No | 454 | 93 | |
| Type of side effects | Anemia | 16 | 47 |
| Rash | 14 | 41.2 | |
| Eye discharge | 2 | 5.9 | |
| Other** | 2 | 5.9 | |
| Regimen change | Yes | 281 | 57.6 |
| No | 207 | 42.4 | |
| Reason for change | Drug side effects | 34 | 12 |
| New drug availability | 104 | 36.8 | |
| Drug out of stock | 82 | 29 | |
| New tuberculosis | 6 | 2.1 | |
| Virologic failure | 25 | 8.8 | |
| Weight > 25 kg | 32 | 11.3 | |
| Adherence level | Good | 406 | 83.2 |
| Fair | 38 | 7.8 | |
| Poor | 44 | 9 |
Notes: *HIV wasting syndrome, extra pulmonary tuberculosis, parotid enlargement; **fatigue and nausea.
Nutritional Information of Children on ART in Northeast Ethiopia, 2020
| Variable | Frequency | Percent | |
|---|---|---|---|
| Weight for height/length (<5 year) | Normal | 122 | 83 |
| Wasted | 25 | 17 | |
| Weight for age (age<10 year) | Normal | 267 | 75.4 |
| Underweight | 87 | 24.6 | |
| Body mass index for age (≥ 5 years) | Normal weight | 299 | 87.7 |
| Thin | 42 | 12.3 | |
| Height/length for age (<15 years) | Normal | 404 | 82.8 |
| Stunted | 84 | 17.2 |
Cox Regression Analysis for Predictors of Loss to Follow-Up Among Children on ART in Northeast Ethiopia, 2020
| Variable | Status | CHR with CI | AHR with CI | P-value | |
|---|---|---|---|---|---|
| LTFU | Censored | ||||
| Age ≥5 years | 58(17%) | 283(83%) | 1 | 1 | |
| 1–5 years | 39(31.2%) | 86(68.8%) | 1.9(1.28,2.90) | 1.6(1.05, 2.46) | 0.030* |
| <1 years | 4(18.2%) | 18(81.8%) | 1.2(0.43, 3.28) | 0.6 (0.21,1.94) | 0.426 |
| Sex: Male | 71(27.5%) | 187(72.5%) | 2.4(1.55–3.65) | 2.1(1.37, 3. 34) | 0.001** |
| Female | 30(13%) | 200(87%) | 1 | 1 | |
| Residence: Urban | 66(17.8%) | 305 (82.2%) | 1 | 1 | |
| Rural | 35(29.9%) | 82(70.1%) | 2(1.34–3.04) | 1.3 (0.88,2.06) | 0.176 |
| Taking prophylaxis | |||||
| Yes | 88(19.5%) | 364 (80.5%) | 1 | 1 | |
| No | 13(36.1%) | 23(63.9%) | 2.7(1.52,4.91) | 0.9(0.46,1.71) | 0.718 |
| Regimen change | |||||
| Yes | 43(15.3%) | 238(84.7%) | 1 | 1 | |
| No | 58(28%) | 149(72%) | 4.3(2.84–6.41) | 4.1(2.59,6.45) | 0.000** |
| CD4 count | |||||
| ≥350 cells | 28(12.3%) | 199(87.7%) | 1 | 1 | |
| < 350 cells | 73(28%) | 188(72%) | 2 (1.28–3.06) | 1.5(0.93, 2.41) | 0.094 |
| Hemoglobin | |||||
| ≥10 mg/dl | 75(17.4%) | 356(82.6%) | 1 | 1 | |
| <10 mg/dl | 26(45.6%) | 31(54.4%) | 2.7(1.73, 4.23) | 1.3 (0.81, 2.16) | 0.267 |
| Height/L for age | |||||
| Normal | 63(15.6%) | 341(84.4%) | 1 | 1 | |
| Stunted | 38(45.2%) | 46(54.8%) | 3.6(2.38,5.39) | 2.2(1.43, 3.44) | 0.000** |
| WHO stage | |||||
| Stage I &II | 42(13.8%) | 263(86.2%) | 1 | 1 | |
| Stage III&IV | 59(32.2%) | 124(67.8%) | 2.1(1.43,3.16) | 2.2(1.40,3.34) | 0.000** |
| Treatment adherence | |||||
| Good | 53(13.1%) | 353(86.9%) | 1 | 1 | |
| Fair | 12(31.6%) | 26(68.4%) | 2.8(1.50,5.26) 8.6(5.64, | 2.2 (1.14,4.20) | 0.019* |
| Poor | 36(81.8%) | 8(18.2%) | 13.2) | 6.6(4.11,10.56) | 0.000** |
Notes: *Statistically significant predictors. **Statistically highly significant predictors.